Can I read Fludarabine, Cytosine Arabinoside, Granulocyte-colony Stimulating Factor with or Without Idarubicin in the Treatment of High Risk Acute Leukaemia or Myelodysplastic Syndromes on EtoBox?

Fludarabine, Cytosine Arabinoside, Granulocyte-colony Stimulating Factor with or Without Idarubicin in the Treatment of High Risk Acute Leukaemia or Myelodysplastic Syndromes by Andres Virchis; Mickey Koh; Peter Rankin; Atul Mehta; Michael Potter; A. Victor Hoffbrand; H. Grant Prentice is a Medicine article available to read on EtoBox.

What is Fludarabine, Cytosine Arabinoside, Granulocyte-colony Stimulating Factor with or Without Idarubicin in the Treatment of High Risk Acute Leukaemia or Myelodysplastic Syndromes about?

## Summary The combination of fludarabine (FDR), high dose cytarabine and granulocyte colony stimulating factor (FLAG) with or without idarubicin (Ida) was used in the treatment of poor risk acute leukaemia or myelodysplastic syndrome (MDS) in a single centre experience. A total of 105 patients were treated over a 4‐year period with 59% achieving a complete remission (CR); no statistical difference observed between FLAG and FLAG‐Ida. For patients responding to FLAG ± Ida, the median event‐free survival (EFS) was 11 months and 23% at 5 years. Such patients proceeded either to further chemotherapy or a haematopoietic stem cell transplant (HSCT). The median EFS (13 months vs. 8 months) and projected 5‐year survival (37% vs. 13%) of patients undergoing HSCT was significantly better than those who did not (__P__ = 0.021). In all, 14 of 72 patients remain alive in continuing CR (median duration 43 months) with 10 of 31 having had a HSCT vs. four of 41 that did not (__P__ = 0·033). Both regimens were well tolerated, with the majority of patients experiencing grade 1 or less non‐haematological toxicity (mainly nausea and vomiting). The median time to neutrophil and platelet recovery was 28

Who reads Fludarabine, Cytosine Arabinoside, Granulocyte-colony Stimulating Factor with or Without Idarubicin in the Treatment of High Risk Acute Leukaemia or Myelodysplastic Syndromes?

Author

Andres Virchis; Mickey Koh; Peter Rankin; Atul Mehta; Michael Potter; A. Victor Hoffbrand; H. Grant Prentice

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 0007-1048)

Published

2003

Language

EN

Field

Medicine (Health Sciences)